Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1741980 | PMC |
| http://dx.doi.org/10.1136/pmj.77.906.265 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A human histidyl-tRNA synthetase splice variant therapeutic targets NRP2 to resolve lung inflammation and fibrosis.
Sci Transl Med
March 2025
Department of Molecular Medicine, Scripps Research Institute, La Jolla, CA 92037, USA.
Interstitial lung disease (ILD) consists of a group of immune-mediated disorders that can cause inflammation and progressive fibrosis of the lungs, representing an area of unmet medical need given the lack of disease-modifying therapies and toxicities associated with current treatment options. Tissue-specific splice variants (SVs) of human aminoacyl-tRNA synthetases (aaRSs) are catalytic nulls thought to confer regulatory functions. One example from human histidyl-tRNA synthetase (HARS), termed HARS because the splicing event resulted in a protein encompassing the WHEP-TRS domain of HARS (a structurally conserved domain found in multiple aaRSs), is enriched in human lung and up-regulated by inflammatory cytokines in lung and immune cells.
View Article and Find Full Text PDF[Cutaneous manifestations of sarcoidosis].
Dermatologie (Heidelb)
March 2025
Klinik für Dermatologie und Venerologie, Medizinische Fakultät, Universität zu Köln und Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
Sarcoidosis is a noninfectious, inflammatory multisystem disorder characterized by the idiopathic formation of granulomas. The pathogenesis of sarcoidosis remains only partially understood, although various clinical risk factors and extrinsic triggers have been identified, alongside a maintained Th1-mediated immune response. Clinically, sarcoidosis can present with specific manifestations associated with sarcoidal granulomas observable in histological examinations, as well as nonspecific manifestations.
View Article and Find Full Text PDFMinor salivary gland biopsy in the diagnosis of definite ocular sarcoidosis in paediatric granulomatous uveitis.
Pediatr Rheumatol Online J
March 2025
Paediatric Clinical Immunology, Pellegrin Hospital, INSERM CICP, University Hospital Centre of Bordeaux, Bordeaux, CIC1401, France.
Background: Non-infectious paediatric granulomatous uveitis (PGU) is a rare disease that is idiopathic in more than half of affected children. The diagnosis of definite ocular sarcoidosis (OS) must be supported by the presence of non-caseating granulomas detected in biopsy, and is therefore a challenge in children with PGU. This study investigated the utility of minor salivary gland biopsy (MSGB) in the diagnosis of definite OS in PGU.
View Article and Find Full Text PDFTattoo Reaction in a Patient With Systemic Sarcoidosis.
Clin Case Rep
March 2025
Department of Internal Medicine, Division of Immunology The University of Iowa Hospitals and Clinics Iowa City Iowa USA.
Papulo-nodular tattoo reactions can be a key diagnostic clue to an underlying diagnosis of sarcoidosis. Identification of such reactions may justify evaluation by rheumatology to assess for systemic manifestations.
View Article and Find Full Text PDFTargeted proteomics in extracellular vesicles identifies biomarkers predictive for therapeutic response in sarcoidosis.
ERJ Open Res
March 2025
ILD Center of Excellence, member of European Reference Network-Lung, St Antonius Hospital, Nieuwegein, The Netherlands.
Background: ∼30% of patients with sarcoidosis, a systemic granulomatous disease of unknown cause, need treatment to alleviate symptoms or prevent organ damage. Prednisone and methotrexate (MTX) are the most commonly used drugs; however, success of treatment varies from patient to patient. In this study, we search for biomarkers and pathways that predict response to treatment with prednisone or MTX in extracellular vesicles (EVs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!